AU2021217172A1 - Lipid prodrugs of neurosteroids - Google Patents

Lipid prodrugs of neurosteroids Download PDF

Info

Publication number
AU2021217172A1
AU2021217172A1 AU2021217172A AU2021217172A AU2021217172A1 AU 2021217172 A1 AU2021217172 A1 AU 2021217172A1 AU 2021217172 A AU2021217172 A AU 2021217172A AU 2021217172 A AU2021217172 A AU 2021217172A AU 2021217172 A1 AU2021217172 A1 AU 2021217172A1
Authority
AU
Australia
Prior art keywords
acid
disease
nitrogen
sulfur
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021217172A
Other languages
English (en)
Inventor
Daniel Kenneth BONNER
Sifei HAN
Luojuan HU
Christopher John Porter
Tim QUACH
Rishab R. SHYAM
Jamie SIMPSON
Natalie TREVASKIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monash University
Seaport Therapeutics Inc
Original Assignee
Monash University
Seaport Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monash University, Seaport Therapeutics Inc filed Critical Monash University
Publication of AU2021217172A1 publication Critical patent/AU2021217172A1/en
Assigned to MONASH UNIVERSITY, SEAPORT THERAPEUTICS, INC. reassignment MONASH UNIVERSITY Request for Assignment Assignors: MONASH UNIVERSITY, PURETECH LYT, INC.
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J69/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one atom and expansion of only one ring by one atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2021217172A 2020-02-05 2021-02-05 Lipid prodrugs of neurosteroids Pending AU2021217172A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062970607P 2020-02-05 2020-02-05
US62/970,607 2020-02-05
US202063009533P 2020-04-14 2020-04-14
US63/009,533 2020-04-14
US202063070064P 2020-08-25 2020-08-25
US63/070,064 2020-08-25
PCT/US2021/016955 WO2021159021A1 (en) 2020-02-05 2021-02-05 Lipid prodrugs of neurosteroids

Publications (1)

Publication Number Publication Date
AU2021217172A1 true AU2021217172A1 (en) 2022-09-22

Family

ID=77199623

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021217172A Pending AU2021217172A1 (en) 2020-02-05 2021-02-05 Lipid prodrugs of neurosteroids

Country Status (9)

Country Link
US (4) US20210268115A1 (https=)
EP (1) EP4100017A4 (https=)
JP (1) JP7810970B2 (https=)
KR (1) KR20220149534A (https=)
CN (1) CN115348864A (https=)
AU (1) AU2021217172A1 (https=)
CA (1) CA3166908A1 (https=)
IL (2) IL295362A (https=)
WO (1) WO2021159021A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL295362A (en) 2020-02-05 2022-10-01 Puretech Lyt Inc Lipid drug inhibitors of neurosteroids
IL295902A (en) * 2020-02-27 2022-10-01 Brii Biosciences Inc Drug inhibitors of neuroactive steroids
CN113980029B (zh) * 2021-10-26 2023-05-23 沈阳药科大学 Sn38类甘油三酯前药、脂质制剂及其制备方法和应用
WO2023086438A1 (en) * 2021-11-10 2023-05-19 Emory University Prodrugs of neurosteroid analogs and uses thereof
EP4704905A1 (en) * 2023-05-02 2026-03-11 Sage Therapeutics, LLC Lymphatic system-targeting compounds
AU2024319589A1 (en) 2023-08-10 2026-01-29 Alto Neuroscience, Inc. Method of treating a depressive disorder and selection of patients benefiting from agomelatine based on eeg measurements
WO2025080689A1 (en) * 2023-10-10 2025-04-17 Seaport Therapeutics, Inc. Lipid prodrugs of bromolysergide and uses thereof
WO2025106418A1 (en) * 2023-11-13 2025-05-22 Seaport Therapeutics, Inc. Lipid prodrugs of allopregnanolone and uses thereof

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3834132A1 (de) 1988-10-07 1990-04-12 Knoll Ag Hydroxypropafenonglyceride
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
ATE286884T1 (de) 1996-03-28 2005-01-15 Shionogi & Co Durch lymphe absorbierbare imidazolderivate
US5962440A (en) 1996-05-09 1999-10-05 Bristol-Myers Squibb Company Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method
US6200530B1 (en) * 2000-03-09 2001-03-13 Michael Markels, Jr. Method of sequestering carbon dioxide with spiral fertilization
US6013665A (en) 1997-12-16 2000-01-11 Abbott Laboratories Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides
US7635690B2 (en) 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
DE60037345T2 (de) 1999-12-10 2008-11-13 Pfizer Products Inc., Groton Pyrrolo(2,3-d)pyrimidin-Verbindungen
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
JP4324343B2 (ja) 2001-04-24 2009-09-02 富士フイルム株式会社 トリヨードフェニル基及びステロイド残基を有する化合物
DE60217322T2 (de) 2001-04-27 2007-10-04 Zenyaku Kogyo K.K. Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
PT1536827E (pt) 2002-08-14 2009-03-20 Silence Therapeutics Ag Utilização de proteína cinase n beta
AU2004228668B2 (en) 2003-04-03 2011-10-27 Park Funding, Llc PI-3 kinase inhibitor prodrugs
ES2382377T3 (es) 2003-05-30 2012-06-07 Gemin X Pharmaceuticals Canada Inc. Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer
EP1692153A4 (en) 2003-07-03 2007-03-21 Univ Pennsylvania INHIBITION OF EXPRESSION OF SYK-KINASE
CN1867664A (zh) 2003-10-17 2006-11-22 兰贝克赛实验室有限公司 使用新的链霉菌菌种生产他克莫司(fk－506)
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
JP4806680B2 (ja) 2004-05-19 2011-11-02 メダレックス インコーポレイテッド 自己犠牲リンカー及び薬剤複合体
AU2006206458B2 (en) 2005-01-19 2012-10-25 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
PL1888550T3 (pl) 2005-05-12 2014-12-31 Abbvie Bahamas Ltd Promotory apoptozy
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
US7989622B2 (en) 2005-10-07 2011-08-02 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use
JP5191391B2 (ja) 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
US20090023805A1 (en) 2006-02-13 2009-01-22 Anne Claire Marrast Method of administration
WO2007129161A2 (en) 2006-04-26 2007-11-15 F. Hoffmann-La Roche Ag Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
TW200824713A (en) 2006-10-18 2008-06-16 Wyeth Corp Processes for the synthesis of individual isomers of mono-PEG CCI-779
KR101566840B1 (ko) 2007-03-12 2015-11-06 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
CN101730706B (zh) 2007-05-11 2015-04-15 生物科技研究有限公司 具有神经保护和增强记忆活性的受体拮抗剂
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
KR100975520B1 (ko) 2008-02-01 2010-08-12 종근당바이오 주식회사 마이코페놀레이트 모페틸의 개선된 제조방법
EP2260052A4 (en) * 2008-02-26 2013-01-16 Univ Emory STEROIDANALOGA FOR NEUROPROTEKTION
HUE029767T2 (en) 2008-03-11 2017-04-28 Incyte Holdings Corp JAK inhibitor azetidine and cyclobutane derivatives
JP5757864B2 (ja) 2008-05-20 2015-08-05 ニューロジェシックス， インコーポレイテッド 水溶性アセトアミノフェン類似体
US8648119B2 (en) 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
CN101676291B (zh) 2008-09-18 2012-05-09 上海海和药物研究开发有限公司 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
US8535655B2 (en) * 2008-10-10 2013-09-17 Polyactiva Pty Ltd. Biodegradable polymer—bioactive moiety conjugates
WO2011051967A2 (en) 2009-10-23 2011-05-05 Alkem Laboratories Ltd Pharmaceutical compositions comprising mycophenolate and processes for preparing thereof
US20110213028A1 (en) 2010-02-26 2011-09-01 Catabasis Pharmaceuticals, Inc. Fatty acid mycophenolate derivatives and their uses
US20130245253A1 (en) 2010-03-26 2013-09-19 Department Of Veterans Affairs Conjugated Neuroactive Steroid Compositions And Methods Of Use
WO2012131019A1 (en) 2011-04-01 2012-10-04 Sandoz Ag Regioselective acylation of rapamycin at the c-42 position
ES3018133T3 (en) 2011-11-30 2025-05-14 Univ Emory Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
GB201304662D0 (en) 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions
AU2015210833B2 (en) 2014-02-03 2019-01-03 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
CN117088931A (zh) * 2014-08-12 2023-11-21 莫纳什大学 定向淋巴的前药
US11738087B2 (en) * 2015-09-08 2023-08-29 Monash University Lymph directing prodrugs
AU2016354564B2 (en) 2015-11-12 2021-04-29 Board Of Regents Of The University Of Nebraska Polyethylene glycol-conjugated glucocorticoid prodrugs and compositions and methods thereof
CN110418796A (zh) 2017-03-08 2019-11-05 施万生物制药研发Ip有限责任公司 托法替尼(tofacitinib)的葡萄糖苷酸前药
CA3068462A1 (en) 2017-06-23 2019-12-27 The Board Of Trustees Of The University Of Illinois Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof
US20190065544A1 (en) 2017-08-29 2019-02-28 Walmart Apollo, Llc System and method for collaborative sharing of database information
CA3077739A1 (en) 2017-08-29 2019-03-07 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
AR116659A1 (es) * 2018-05-04 2021-06-02 Acerus Pharmaceuticals Corp Derivados de neuroesteroides y usos de estos
CA3107481A1 (en) 2018-08-02 2020-02-06 Puretech Lyt, Inc. Lipid prodrugs of pregnane neurosteroids and uses thereof
WO2020176856A1 (en) 2019-02-28 2020-09-03 Puretech Lyt, Inc. Lipid prodrugs of glucocorticoids and uses thereof
IL295362A (en) 2020-02-05 2022-10-01 Puretech Lyt Inc Lipid drug inhibitors of neurosteroids

Also Published As

Publication number Publication date
US20210268115A1 (en) 2021-09-02
US20230338552A1 (en) 2023-10-26
CN115348864A (zh) 2022-11-15
US20220395513A1 (en) 2022-12-15
EP4100017A4 (en) 2024-04-10
US11975073B2 (en) 2024-05-07
WO2021159021A1 (en) 2021-08-12
IL295362A (en) 2022-10-01
JP2023514147A (ja) 2023-04-05
KR20220149534A (ko) 2022-11-08
US20240245788A1 (en) 2024-07-25
CA3166908A1 (en) 2021-08-12
IL326763A (en) 2026-04-01
EP4100017A1 (en) 2022-12-14
JP7810970B2 (ja) 2026-02-04

Similar Documents

Publication Publication Date Title
US11975073B2 (en) Lipid prodrugs of neurosteroids
CN112703003B (zh) 孕烷神经类固醇的脂质前药及其用途
US12178875B2 (en) Lymphatic system-directing lipid prodrugs
AU2021269278B2 (en) Lymph directing prodrugs
US11883497B2 (en) Lymphatic system-directing lipid prodrugs
AU2020228662A1 (en) Lipid prodrugs of JAK inhibitors and uses thereof
WO2020176868A1 (en) Lipid prodrugs of btk inhibitors and uses thereof
WO2020176856A1 (en) Lipid prodrugs of glucocorticoids and uses thereof
WO2019126378A1 (en) Lipid prodrugs of mycophenolic acid and uses thereof
HK40084022A (en) Lipid prodrugs of neurosteroids
HK40105719A (en) Lymphatic system-directing lipid prodrugs

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: MONASH UNIVERSITY

Free format text: FORMER APPLICANT(S): PURETECH LYT, INC.; MONASH UNIVERSITY

Owner name: SEAPORT THERAPEUTICS, INC.

Free format text: FORMER APPLICANT(S): PURETECH LYT, INC.; MONASH UNIVERSITY